As generic entry looms for its cash cow, Jazz wins FDA nod for follow-up sleep disorder drug
After a 3-month delay attributed to labelling discussions, Jazz Pharmaceuticals $JAZZ has notched an approval for its wake-promoting drug solriamfetol, now christened Sunosi.
Like Xyrem …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.